Report
Pharmaceuticals Biogen: Read-across from Q2 figures for European companies
PharmaceuticalsBiogen: Read-across from Q2 figures for European companies
Good sequential growth in MS
In-there Ocrevus is still shining
Early days to detect any change in trend for Spinraza
Biogen’s biosimilar (anti-TNF) franchise is growing steadily
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Eric Le Berrigaud
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.